PPI when and where
-
Upload
vadivel-kumaran-sivasankaran -
Category
Health & Medicine
-
view
590 -
download
0
Transcript of PPI when and where
PPI’S – AN OVERVIEW
DR S.VADIVEL KUARANCONSULTANT MEDICAL GASTROENTEROLOGIST
AND HEPATOLOGIST
KAUVERY HOSPITAL,ALWARPETCHENNAI
INTRODUCTION• Decrease gastric acid secretion by inhibiting
gastric H⁺K⁺-ATPase .
• Omeprazole first PPI- 1989.
• PPI’s are weak bases that concentrate in acidic spaces with pKa1- 3-8 to 4.5.
• PPI’s are metabolised by CYP2C19 and CYP3A4.
• Rabeprazole has higher affinity for CYP3A4.
• Conc. of PPI in secretory canaliculus is 100000 to 1000000 higher than in blood.
• All PPI bind to cysteine 813.
• Omeprazole- cysteine 892 Lansoprazole- cysteine 321 Pantoprazole – cysteine 822
INDICATIONS• PEPTIC ULCER DISEASE• TREATMENT AND PREVENTION OF
GASTRODUODENAL ULCERS DUE TO NASAID.• ERADICATION OF H.PYLORI• ZOLLINGER ELLISON SYNDROME• BARRETT’S METAPLASIA• GASTROESOPHAGEAL REFLUX DISEASE• ESOPHAGEAL STRICTURES• EXTRAESOPHAGEAL MANIFESTATIONS
pKa??• It refers to degree of willingness of compoud
to accept or donate a proton.
• Compound with pKa of 5 is 10 fold more basic than compound with pKa of 4.
SITE OF ACTION
GASTRIC H⁺K-ATPase• Found in parietal cells and small amounts in
renal medulla.
• It has α and β subunits.
• 3 types F, V1, P1 and P2.
COMMON SIDE EFFECTS• 2812 pts on
OMEPRAZOLE
Headache(2.4%) Diarrhea (1.9%) Nausea(0.9%) Rash( 1.1%)
• 5669 pts on Lansoprazole
Diarrhea(4.1%) Headache(2.9%). Nausea( 2.6%)
ADVERSE EFFECTS• Physiological Hypergastrinemia• Fundic gland Polyposis• Drug interactions• Vit B12 metabolism and pernicious anemia• Osteopenia and osteoporosis• Community acquired pneumonia• Bacterial overgrowth
HYPERGASTRINEMIA• PPI’s cause physiological hypergastrinemia.
• Hypergastrinemia causing ECL Hyperplasia is controversial.
• Only one published report of ECL Hyperplasia and gastric malignancy in ZES pt treated with high dose PPI.
FUNDIC GLAND POLYPOSIS(FGP)• PPI use leads to 4 fold risk of Fundic gland
polyposis.
• H.pylori also increases risk of FGP.
• Eradication of H.pylori or stopping PPI leads to regression of polyposis.
• It doesn’t lead to Adenocarcinoma.
DRUG INTERACTIONS• All PPI’s metabolized by CYP2C19 except
Rabeprazole high affinity for CYP3A4.
• Reduce absorption and bioavailability of ketoconazole, Itraconazole and sucralfate.
• All PPI’s except Pantoprazole affect the effectiveness of clopidogrel- 40% risk of coronary stent occlusion.
IRON & B12
• To small extent affect iron absorption.
• Elderly and ZES pts on high dose PPI have reduced B12 concentration.
PPI and Metabolic bone disease???
• PPI > 5 yrs risk of osteoporosis by 1.62 fold
• PPI > 7 yrs risk of osteoporosis by 4.55 fold.
• Rarely osteoporotic fractures reported even with 6- 12 months of high dose PPI.
CAP
• PPI use leads to bacterial colonization of stomach and pulmonary micro aspirations.
• Odd’s ratio is 1.89 for current PPI use , 1.55 for past PPI use.
• On contrary PPI do not increase risk of HAP.
PPI & SIBO??
• PPI postulated as one of etiological factor for SIBO due to reduced acid provacating bacterial colonization of GIT.
• Clostridium difficile infection.
RABEPRAZOLE
“CAPRIE/CREDO”
Trials favouring Gastros• PLATO TRIAL
• COGENT TRIAL
• TRITON TRIAL
ADD PPI-PANTO/RABE/LANSO/DEXLAN
SO
ANY OF FOLLOWINGADVANCED AGE/ H.PYLORI/ NSAID USE
YES NO
PATIENT TAKING CLOPIDOGREL
HISTORY OF GI BLEED
NOVEL STRATEGIES• TENATOPRAZOLE• DEXLANSOPRAZOLE MR• “VECAM”
TAKE HOME MESSAGE• PPI TO BE ADMINISTERED 30 MIN BEFORE BREAKFAST.
• TWICE DOSAGE FOR MAXIMAL ACID SUPPRESSION.
• RABEPRAZOLE ACID LABILE, RAPID ONSET OF ACTION.
• RATIONALIZE CONCOMITANT USE OF PPI AND ANTIPLATELETS.
• RCT’S – OMEPRAZOLE & ESOMEPRAZOLE MORE INTERACTIONS WITH ANTIPLATELETS